Agrify Corporation (AGFY)
NASDAQ: AGFY · Real-Time Price · USD
24.74
-1.07 (-4.15%)
At close: Aug 1, 2025, 4:00 PM
26.20
+1.46 (5.90%)
After-hours: Aug 1, 2025, 4:20 PM EDT
CTI BioPharma Stock Forecast
Stock Price Forecast
There is currently no analyst price target forecast available for CTI BioPharma.
Price Target: $0.00 (0.00%)
Analyst Consensus: n/a
Analyst Ratings
There are currently no analyst ratings available for CTI BioPharma.
Recommendation Trends
| Rating | Jun '22 | Jul '22 | Aug '22 | Sep '22 | Oct '22 | Nov '22 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 1 | 1 | 1 | 0 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 1 | 1 | 1 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 2 | 2 | 2 | 2 | 0 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Alliance Global Partners | Alliance Global Partners | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | Nov 10, 2022 |
| Roth Capital | Roth Capital | Strong Buy → Hold Downgrades $4,500 | Strong Buy → Hold | Downgrades | $4,500 | +18,089.17% | Aug 16, 2022 |
| Craig-Hallum | Craig-Hallum | Strong Buy Maintains $96,000 → $37,500 | Strong Buy | Maintains | $96,000 → $37,500 | +151,476.39% | Mar 22, 2022 |
| Roth Capital | Roth Capital | Strong Buy Maintains $60,000 → $93,000 | Strong Buy | Maintains | $60,000 → $93,000 | +375,809.46% | Aug 13, 2021 |
| Craig-Hallum | Craig-Hallum | Strong Buy Initiates $75,000 | Strong Buy | Initiates | $75,000 | +303,052.79% | Jul 23, 2021 |
Financial Forecast
Revenue This Year
n/a
from 9.68M
Revenue Next Year
n/a
EPS This Year
n/a
from -40.92
EPS Next Year
n/a
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue |
|---|
| High |
| Avg |
| Low |
Revenue Growth
| Revenue Growth |
|---|
| High |
| Avg |
| Low |
EPS Forecast
| EPS |
|---|
| High |
| Avg |
| Low |
EPS Growth
| EPS Growth |
|---|
| High |
| Avg |
| Low |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.